Back to news list

Share

  • ASCO-2025-highlights-1022x454 1

Brain Tumour Group,Genito-Urinary Cancers Group,Head and Neck Cancer Group,Melanoma Group,News

EORTC’s presence at ASCO 2025

28 May 2025

At EORTC, we are delighted to be participating in the ASCO 2025 Annual Meeting, taking place from 30 May to 3 June in Chicago. During the event, we will present eight significant abstracts, comprising three oral presentations and five posters. These will highlight our latest findings in brain tumours, melanomas, breast cancer, head and neck cancers, lung cancer, and genitourinary cancers.

Please refer to the table below for further details.

EORTC Abstracts Practical information
Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990.
Martin Van Den Bent		 Date: Friday, 30 May 2025
Time: 15:09-15:21 CDT
Type: Oral Abstract Session
Room: S100bc | Live stream
Abstract: 2002
Primary analysis of the EORTC-2139-MG/Columbus-AD trial: A randomized trial of adjuvant encorafenib and binimetinib versus placebo in high-risk stage II melanoma with a BRAF-V600E/K mutation.
Alexander van Akkooi		 Date: Tuesday, 3 June 2025
Time: 09:57-10:09 CDT
Type: Oral Abstract Session
Room: S100a | Live Stream
Abstract: LBA9501
EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA).
Michail Ignatiadis		 Date: Monday, 2 June 2025
Type: Poster Session
Room: Hall A – Posters and Exhibits
Abstract: TPS620
Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM).
Jean-Pascal H. Machiels		 Date: Monday, 2 June 2025
Type: Poster Session
Room: Hall A – Posters and Exhibits
Abstract: 6028
Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.
Nicolas Girard		 Date: Sunday, 1 June 2025
Time: 17:36-17:42 CDT
Type: Rapid Oral Abstract Session
Room: Hall D1 | Live Stream
Abstract: 8016
PSA and alkaline phosphatase changes in the EORTC-1333 PEACE-3 study evaluating the addition of six cycles of radium 223 in metastatic castration-resistant prostate cancer (mCRPC) starting enzalutamide.
Andrey Soares		 Date: Monday, 2 June 2025
Type: Poster Session
Room: Hall A – Posters and Exhibits
Abstract: 5062
Mechanisms of resistance to anti-PD1 treatment in recurrent and/or metastatic squamous cell carcinoma of the head and neck: A multi-omics IMMUCAN/EORTC analysis.
Athénaïs van der Elst		 Date: Monday, 2 June 2025
Type: Poster Session
Room: Hall A – Posters and Exhibits
Abstract: 6050
The tumoral molecular landscape of long-term survivors with isocitrate dehydrogenase wildtype glioblastoma: Lessons from ETERNITY (EORTC 1419).
Michael Weller		 Date: Saturday, 31 May 2025
Type: Poster Session
Room: Hall A – Posters and Exhibits
Abstract: 2059
Back to news list

Related News

  • New study confirms a key quality of life tool can be used with adolescents with cancer

    9 Jun 2026

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

    8 Jun 2026

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

    20 May 2026

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

    1 May 2026

  • EORTC’s presence at ESTRO 2026

    30 Apr 2026

  • Independent, academic cancer trials are vital to improve patient outcomes worldwide

    28 Apr 2026

  • EORTC Imaging Group Becomes the Diagnostic and Therapeutic Imaging Group

    24 Apr 2026

  • Investing in the future of cancer research; EORTC’s Young and Early Career investigator Network shows its value

    23 Apr 2026

  • In Memoriam of Martine Van Glabbeke (1951-2026)

    17 Apr 2026

  • PEACE-3 trial demonstrates significant overall survival benefit in patients with metastatic castration-resistant prostate cancer with bone metastases

    27 Feb 2026